187 related articles for article (PubMed ID: 32769767)
1. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment.
Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS
AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767
[No Abstract] [Full Text] [Related]
2. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
D'Amico F; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
[No Abstract] [Full Text] [Related]
6. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
8. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
10. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab.
Ma C; Kotze PG; Almutairdi A; Jairath V; Panaccione R
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2374-2376.e2. PubMed ID: 30528845
[TBL] [Abstract][Full Text] [Related]
12. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
Hendy P; Hart A
Aliment Pharmacol Ther; 2015 Jan; 41(1):149. PubMed ID: 25483435
[No Abstract] [Full Text] [Related]
13. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
14. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
17. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
Hinojosa Del Val J; Barreiro-de Acosta M
Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
[TBL] [Abstract][Full Text] [Related]
18. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
Zoet ID; de Boer NK; de Meij TG
J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
[No Abstract] [Full Text] [Related]
19. Response to vedolizumab for children with steroid-refractory Ulcerative Colitis unresponsive to anti-TNF.
Wiskin AE; Paul SP; Spray CH
Acta Paediatr; 2019 Jul; 108(7):1359-1360. PubMed ID: 30788859
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
